SOST and osteoporosis: Osteoporosis is characterized by skeletal fragility and microarchitectural deterioration with an increased risk of fragility fractures, which is the most common metabolic diseases of the skeletal system, causing a major economic burden worldwide.[1, 2, 3] Most primary osteoporosis is attributed to excessive bone resorption and/or defects in bone formation.[4] In recent years, the application of anabolic agents, including teriparatide (ligand binding to parathyroid hormone receptor type 1) and romosozumab (humanized monoclonal antibody to sclerostin), has improved osteoporosis treatment.